119 related articles for article (PubMed ID: 38384043)
1. Expression of BRCA1 by immunohistochemistry and its association with ER, PR, Her2neu status in infiltrative ductal carcinoma of breast.
Soman PS; Hemalatha A; Sreeramulu PN
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S706-S711. PubMed ID: 38384043
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
[TBL] [Abstract][Full Text] [Related]
3. Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens.
Verma D; Agarwal K; Tudu SK
Indian J Pathol Microbiol; 2018; 61(1):31-38. PubMed ID: 29567881
[TBL] [Abstract][Full Text] [Related]
4. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment.
Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F
J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394
[TBL] [Abstract][Full Text] [Related]
9. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
10. Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.
Tsai YM; Hsu HM; Chen CJ; Hsu KF; Fan HL; Chang H; Chan DC; Yu JC
Ir J Med Sci; 2014 Mar; 183(1):71-5. PubMed ID: 23757214
[TBL] [Abstract][Full Text] [Related]
11. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC;
Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761
[TBL] [Abstract][Full Text] [Related]
12. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
13. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
15. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
[TBL] [Abstract][Full Text] [Related]
16. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
[TBL] [Abstract][Full Text] [Related]
17. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
19. Effect of neoadjuvant therapy on breast cancer biomarker profile.
Rey-Vargas L; Mejía-Henao JC; Sanabria-Salas MC; Serrano-Gomez SJ
BMC Cancer; 2020 Jul; 20(1):675. PubMed ID: 32682413
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
